May 22, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
May 11, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
Apr 29, 2020 • 8:05 am EDT Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Results in Arthritis & Rheumatology
Mar 12, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
Mar 10, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Mar 5, 2020 • 8:05 am EST Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
Feb 11, 2020 • 4:01 pm EST Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Feb 7, 2020 • 9:02 am EST Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock